Metagenomi, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

MGX$0.70-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2025	2024	2025	2024
Collaboration revenue	$8,513	$20,008	$12,640	$31,167
Operating expenses:
Research and development	22,507	28,320	47,649	59,759
General and administrative	6,993	8,551	13,798	17,303
Total operating expenses	29,500	36,871	61,447	77,062
Loss from operations	(20,987)	(16,863)	(48,807)	(45,895)
Other income (expense):
Interest income	2,485	3,976	5,372	7,910
Change in fair value of long-term investments	(1,292)	—	(1,292)	—
Other expense, net	(70)	(51)	(78)	(101)
Total other income (expense), net	1,123	3,925	4,002	7,809
Net loss before provision for income taxes	(19,864)	(12,938)	(44,805)	(38,086)
Benefit (provision) for income taxes	(44)	2,199	(142)	2,199
Net loss	$(19,908)	$(10,739)	$(44,947)	$(35,887)
Other comprehensive loss:
Unrealized loss on available-for-sale marketable securities	(249)	13	(337)	(168)
Comprehensive loss	$(20,157)	$(10,726)	$(45,284)	$(36,055)
Net loss per share attributable to common stockholders, basic and diluted	$(0.54)	$(0.29)	$(1.21)	$(1.24)
Weighted average common shares outstanding, basic and diluted	37,156,979	36,625,291	37,088,383	28,901,399

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.